TY  - JOUR
AU  - O'Cearbhaill, Roisin E
AU  - Pérez-Fidalgo, Jose-Alejandro
AU  - Monk, Bradley J
AU  - Tusquets, Ignacio
AU  - McCormick, Colleen
AU  - Fuentes, Jose
AU  - Moore, Richard G
AU  - Vulsteke, Christof
AU  - Shahin, Mark S
AU  - Forget, Frédéric
AU  - Bradley, William H
AU  - Hietanen, Sakari
AU  - O'Malley, David M
AU  - Dørum, Anne
AU  - Slomovitz, Brian M
AU  - Baumann, Klaus
AU  - Selle, Frédéric
AU  - Calvert, Paula M
AU  - Artioli, Grazia
AU  - Levy, Tally
AU  - Kumar, Aalok
AU  - Malinowska, Izabela A
AU  - Li, Yong
AU  - Gupta, Divya
AU  - González-Martín, Antonio
PY  - 2022
DO  - 10.1016/j.ygyno.2022.04.012
UR  - http://hdl.handle.net/10668/22548
T2  - Gynecologic oncology
AB  - To evaluate the association between surgical timing and postoperative residual disease status on the efficacy of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer at high risk of recurrence. Post hoc...
LA  - en
KW  - Maintenance therapy
KW  - Niraparib
KW  - Ovarian cancer
KW  - PARP inhibitor
KW  - Surgery
KW  - Carcinoma, Ovarian Epithelial
KW  - Chemotherapy, Adjuvant
KW  - Cytoreduction Surgical Procedures
KW  - Female
KW  - Humans
KW  - Indazoles
KW  - Neoadjuvant Therapy
KW  - Neoplasm Staging
KW  - Neoplasm, Residual
KW  - Ovarian Neoplasms
KW  - Piperidines
TI  - Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
TY  - research article
VL  - 166
ER  -